TAPI Names Serge Rogasik as CEO to Drive Growth and Competitiveness

TEL AVIV, Israel, Sept. 30, 2026 /CourierPR/ -- TAPI, a global leader in the development and manufacturing of active pharmaceutical ingredients (APIs) and a leading contract development and manufacturing organization (CDMO) partner, has appointed Serge Rogasik as its new Chief Executive Officer. Founded in 1935, TAPI is one of the world’s largest producers of APIs, with a robust portfolio of more than 350 high-quality products and a global footprint in 100+ countries, 13 manufacturing sites, and six research and development (R&D) facilities.

Rogasik, a transformation-focused global executive with over 25 years of experience, will lead the company through its next phase of growth and competitiveness. Rogasik's background includes leading private equity-backed companies through complex carve-outs, accelerated growth, and portfolio transformation. Most recently, he served as President and CEO of Kensing, a specialty ingredients company owned by One Rock Capital Partners, where he helped transform a single-site carve-out from BASF into a global platform serving the personal care, nutrition, pharmaceutical, and agrochemical markets.

Rogasik and the TAPI team will be at CPHI Milan, October 6-8, 2026, in Hall 3, Booth A73. Customers and partners are invited to stop by to meet him and the teams behind TAPI's API and CDMO businesses.

TAPI is a global leader in the development and manufacturing of APIs, building blocks, and key starting materials (KSMs), providing one of the industry's most comprehensive API portfolios. The company also offers customized CDMO services, utilizing their extensive expertise in a wide range of technologies to meet the diverse needs of partners, ensuring flexibility and excellence in every project.

TAPI's operations are integral to the delivery of high-quality, safe, and effective medications to patients worldwide, supported by a sophisticated supply chain, focused innovative manufacturing, regulatory and quality excellence, and a commitment to sustainability. With 4,100 employees and a global footprint in 100+ countries, TAPI's 13 sites worldwide and six R&D facilities are crucial to its mission.

Teva Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance, or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "may," "project," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully execute TAPI's next phase of growth and anticipated business performance; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors" and "Forward-looking statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.